What is HC Wainwright’s Forecast for Erasca FY2026 Earnings?

Erasca, Inc. (NASDAQ:ERAS – Free Report) – Stock analysts at HC Wainwright decreased their FY2026 earnings per share estimates for shares of Erasca in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.54) for the year, down from their prior estimate of ($0.51). HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Erasca’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Erasca’s Q4 2026 earnings at ($0.16) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.07) EPS and FY2030 earnings at ($0.88) EPS.

Erasca (NASDAQ:ERAS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Several other analysts also recently weighed in on ERAS. Leerink Partners began coverage on shares of Erasca in a research note on Tuesday. They issued an “outperform” rating and a $35.00 price target for the company. Bank of America raised their price objective on Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Guggenheim lifted their price objective on Erasca from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research note on Tuesday, September 8th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.17.

Read Our Latest Stock Report on ERAS

Erasca Price Performance

Shares of NASDAQ ERAS opened at $13.76 on Tuesday. Erasca has a one year low of $2.75 and a one year high of $24.28. The firm’s 50 day simple moving average is $14.85 and its two-hundred day simple moving average is $15.32. The stock has a market capitalization of $4.83 billion, a P/E ratio of -13.90 and a beta of 0.68.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Erasca in the 2nd quarter worth $387,544,000. ARCH Venture Management LLC purchased a new position in shares of Erasca in the second quarter valued at about $129,917,324. Janus Henderson Group PLC purchased a new position in shares of Erasca in the first quarter valued at about $59,988,000. Assenagon Asset Management S.A. raised its stake in shares of Erasca by 407.9% during the third quarter. Assenagon Asset Management S.A. now owns 4,128,332 shares of the company’s stock valued at $60,521,000 after acquiring an additional 3,315,456 shares during the last quarter. Finally, Commodore Capital LP bought a new position in shares of Erasca during the first quarter valued at about $51,372,000. 67.78% of the stock is owned by hedge funds and other institutional investors.

Erasca News Summary

Here’s some of the latest news about ERAS:

  • Positive Sentiment: Leerink Partners initiated coverage with an “Outperform” rating and a $35 price target, adding to positive analyst sentiment. Leerink Partners rating
  • Neutral Sentiment: Erasca cited encouraging early ERAS-0015 safety and tolerability and partial responses in its ongoing study. Those early findings are not proof the drug or the new combination will be effective; the pancreatic-cancer trial will need to establish safety and benefit. Clinical collaboration details
  • Negative Sentiment: HC Wainwright lowered several earnings estimates, including its FY2026 estimate, while maintaining a Buy rating and $22 target. Erasca remains a clinical-stage company, so investment prospects depend heavily on clinical progress rather than established product revenue. Erasca analyst coverage

Erasca Company Profile

(Get Free Report)

Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.

Featured Articles

Earnings History and Estimates for Erasca (NASDAQ:ERAS)

Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.